The US Acute Lymphocytic Leukemia (ALL) therapeutics market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Acute lymphocytic/lymphoblastic leukemia (ALL) is a type of cancer that develops from immature lymphocytes. “Acute” here indicates leukemia that quickly progresses and spreads across the body. ALL develops in bone marrow and quickly invades other parts of the body including the liver, spleen, lymph nodes, liver, central nervous system, spleen, central nervous system, and the blood. Symptoms can be non-specific and may include feeling weak and tired, paler skin, bruises, frequent and severe bleeding gums, nose bleeds; weight loss, shortness of breath, and loss of appetite. Various types of therapeutics are used for ALL treatment. Chemotherapy is one of the major therapeutics used for ALL treatment
Market Drivers and Restraints
The market is experiencing growth owing to rise in incidences of acute lymphoblastic leukemia and the number of bone marrow biopsies. In the United States, the total number of Acute Lymphoblastic Leukemia incident cases were 5,816 cases in the year 2017 which are expected to grow during the study period. In addition, the increase in investment in the R&D of different leukemia and rise in awareness of targeted therapies amongst the population further drive the growth of the ALL therapeutics market. Despite these, the stringent regulatory approvals for the therapeutics and the adverse side effects of the drugs used in the therapy impede the growth of the market. For example, Chemo drugs can affect some normal cells in the body, which can lead to side effects. The side effects of chemo depend on the type and dose of drugs given and the length of time they are taken. Also, patent expiry of the blockbuster drugs used in the treatment and the higher costs involved in the therapies limit the growth of ALL(Acute Lymphocytic Leukemia) market